<a href=Medtronic” height=”146″ src=”https://www.medicaldevice-network.com/wp-content/uploads/static-progressive/nri/medicaldevice/news/MEDTRONIC_021012.JPG” style=”padding: 10px” title=”Medtronic corporate headquarters” width=”299″ />

The European Union has granted CE mark approval to Medtronic’s minimally invasive continuous glucose monitor (CGM) for use in hospital critical care units (CCU).

Featuring a subcutaneous sensor, the Sentrino CGM system is designed to optimise glucose management and reduce the length of stay, morbidity and mortality in critically ill patients.

The monitor, which uses Redundant sensing technology for visibility of glycemic variability, displays patients’ interstitial glucose value in real time and provides predictive alarms to facilitate clinicians to intervene and prevent glycemic excursions.

In addition, the system includes a drug interference rejection technology that ensures minimal interference with various pharmaceuticals used in the CCU, as well as a configurable system that integrates into clinical workflow to improve the efficiency of maintaining glucose control.

Glucose control, which is a standard practice for diabetic and non-diabetic patients in the CCU, is difficult to achieve, according to the company.

Academisch Medisch Centrum intensive care medicine department Professor M J Schultz said; "Introduction of the CGM technology in critically ill patients is a high priority that will help improve our insight in insulin resistance, will increase understanding of the effects of glycemic variability and will facilitate any blood glucose control strategy."

Medtronic continuous glucose monitoring business vice president and general manager Greg Meehan said; "Given the market need for CGM in CCU patients, we believe the market potential will exceed $1bn globally."

Sentrino is an investigational device and is not available for sale in the US.

Image: Medtronic corporate headquarters in Fridley, Minnesota, US. Photo: Courtesy of Bobak Ha’Eri.